Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia

[1]  J. Tweed,et al.  A placebo‐controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia , 2000, Acta psychiatrica Scandinavica.

[2]  G. Tollefson,et al.  Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses , 1998, British Journal of Psychiatry.

[3]  H. Fibiger,et al.  Olanzapine: A New Atypical Antipsychotic Drug , 1996, Neuropsychopharmacology.

[4]  J. Peuskens,et al.  Risperidone in the treatment of negative symptoms of schizophrenia: a meta‐analysis , 1995, International clinical psychopharmacology.

[5]  D. Heal,et al.  P-4-15 Zotepine: Preclinical tests predict antipsychotic efficacy and an atypical profile , 1995, European Neuropsychopharmacology.

[6]  D. Sibley,et al.  Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. , 1994, The Journal of pharmacology and experimental therapeutics.

[7]  D. Casey.  Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. , 1993, The Psychiatric clinics of North America.

[8]  M. Singh,et al.  The positive-negative distinction in drug-free schizophrenic patients. Stability, response to neuroleptics, and prognostic significance. , 1989, Archives of general psychiatry.

[9]  S. Marder,et al.  Behavioral toxicity of antipsychotic drugs. , 1987, The Journal of clinical psychiatry.

[10]  R. Baldessarini,et al.  What is the best maintenance dose of neuroleptics in schizophrenia? , 1980, Psychiatry Research.

[11]  J. Davis,et al.  Overview: maintenance therapy in psychiatry: I. Schizophrenia. , 1975, The American journal of psychiatry.

[12]  M. Tohen,et al.  Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. , 1997, Archives of general psychiatry.

[13]  D. Casey.  Side effect profiles of new antipsychotic agents. , 1996, The Journal of clinical psychiatry.

[14]  G. Tollefson,et al.  Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. , 1996, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[15]  P. Weiden,et al.  Atypical antipsychotic drugs and long-term outcome in schizophrenia. , 1996, The Journal of clinical psychiatry.